I have read the statement from Gottlieb yesterday....several times..
This statement in the press release is very critical and gives CVSI a significant edge
Ultimately, we remain committed to exploring an appropriate, efficient and predictable regulatory framework to allow product developers that meet the requirements under our authorities to lawfully market these types of products. The actions we’re announcing today will allow us to continue to clarify our regulatory authority over these products and seek input from a broad range of stakeholders and examine a variety of approaches and considerations in the marketing and regulation of cannabis or cannabis-derived products, while continuing to protect the public’s health and safety.
It was my understanding that the GRAS study that CVSI had done last summer was in line with FDA protocols.....there would be no point in doing such and paying for a toxicology report that would not meet FDA standards.
The hearing will weed out the "bad actors" in the CBD space. I am sure reputable companies will bring to the hearing their scientists, and credible certifications to provided clarification of what they are selling to the public.
We have GRAS and certification from National Hemp Association, as well as documented evidence and traceability of our product from seed to shelf..
The FDA is going to have to determine what is safe and why they think your product is safe.
We are clearly in the drivers seat on this......way ahead of competitors..
Often times, in these situations, its a company's R and D that is ahead of the curve wins.
Some company is going to be the first to get approval.
I like our chances.....
